Dr. Peden\u2019s primary research focus is asthma and airway diseases with an emphasis on the impact of environmental agents and pollutants on respiratory inflammation and physiology, which affects airway conditions such as asthma, COPD, inhalational injury, and airway infections. Dr. Peden has developed several model airway challenge protocols that allow for screening of potential interventions, testing sensor devices, and identification\/confirmation of genetic or physiologic risk factors for pollutant-induced and airway disease. He has developed and led innovative and high quality pre-clinical and Phase I clinical investigations of novel treatments for lung and allergic diseases and served as a site PI for innovative studies assessing mechanisms of action of allergen immunotherapy and allergic responses to mRNA-based SARS-CoV2 vaccines.<\/p>\n
Dr. Peden has additional experience in institutional and large-scale research efforts. This experience includes Dr. Peden overseeing the UNC Screen NC COVID-19 seroprevalence study performed during the pandemic in which COVID-19 antibody status was assessed in >8,000 volunteers over 18 months; serving as the Chief Medical Monitor of the nationwide National Heart, Lung, and Blood Institute funded PreCISE asthma network based at UNC; and serving as a Medical Advisor to the National Center for Advancing Translational Sciences based national Biomedical Data Translator program, which aims to integrate various forms of biomedical data to better understand the pathophysiology of disease. Dr. Peden also has experience as an advisor to the US Food and Drug Administration, having served as Chair of the Allergenic Products Advisory Committee and as an ad hoc<\/em> member of Pulmonary and Allergy Drugs Advisory Committee. He currently serves on an ad hoc<\/em> basis for the Vaccine and Related Biological Products Advisory Committee.<\/p>\n
\nEducation:<\/h3>\n
\n
\nLinks to more information on Dr. Peden:<\/h3>\n
\n